Kobayashi And Osaka University Found Antioxidants From Shiitake Essence Inhibit Hepatitis Symptoms
This article was originally published in PharmAsia News
Kobayashi Pharmaceutical Co. and Osaka University discovered two antioxidants that inhibit Hepatitis symptoms. The substances under research, syringic acid and vallinic acid, are extracted from the essence of Shiitake Mushroom mycelium. The onset of symptoms was delayed and progress of liver fabrication decreased in mice with hepatitis symptoms following treatment with the antioxidants. The universities plan on developing a new drug from the antioxidants that will protect liver cells and could be combined with antivirus drugs such as interferon to prevent cirrhosis and liver cancer. (Click for more-Japanese language) "Kobayashi And Osaka University Found Shiitake Essence Inhibit Hepatitis Symptoms And Confirm Through Test on Mice" - Nikan Industrial News (2/18/08)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.